Nasdaq · CIK 0001408443
MIST Milestone Pharmaceuticals Inc.
Insider trading from SEC Form 4. Last filing Jun 12, 2026. Close $0.76 on Oct 9, 2026, +7% from the 52-week low and -74% from the high.
In brief
Milestone Pharmaceuticals Inc. (MIST) has 41 SEC Form 4 filings on file from 12 insiders, the latest filed on Jun 12, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
7 open-market trades have been scored at MIST. The newest: Joseph Oliveto (President and CEO) sold $82k of stock on Apr 16, 2026, filed Apr 20, 2026, scored 14 (weak), under a 10b5-1 plan. The largest of the 7 shown: Joseph Oliveto (President and CEO) sold $375k on Dec 15, 2025, scored 51 (moderate). 5 insiders sold within 14 days of each other around Dec 15, 2025.
3 Form 144 notices of planned sales are on file, the latest filed Apr 16, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Milestone Pharmaceuticals Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 14Weak | Joseph Oliveto President and CEO sell | $82k 36,500 shares | -8% | +156% from low-29% from high | |
| 36Weak | David Bharucha Chief Medical Officer sell | $158k 70,252 shares | -43% | - | |
| 43Moderate | Amit Hasija CFO & EVP of Corp. Development sell | $158k 70,252 shares | -47% | - | |
| 51Moderate | Joseph Oliveto President and CEO sell | $375k 167,577 shares | -29% | - | |
| 36Weak | Lorenz Muller Chief Commercial Officer sell | $146k 64,746 shares | -26% | - | |
| 51Moderate | Jeffrey Edward Nelson Chief Operating Officer sell | $158k 70,252 shares | -70% | - | |
| 20Weak | Joseph Oliveto President and CEO sell | $98k 43,500 shares | -13% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 16, 2026 | JOSEPH OLIVETO Director, Officer | 36,500 0.03% of outstanding | $80k | Apr 16, 2026 | none |
| Jan 8, 2026 | JOSEPH OLIVETO Director, Officer | 79,500 0.09% of outstanding | $171k | Jan 8, 2026 | $1,125 |
| Jan 7, 2026 | JOSEPH OLIVETO Officer | 500 0.00% of outstanding | $1,025 | Jan 7, 2026 | none |
Transactions
The newest 50 of 88 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | Robert James Wills director | AGrant or award Stock Option (right to buy)derivative | +77,000 | $0.00 | $0 | 77,000 | Jun 12, 2026 |
| Jun 10, 2026 | Seth H. Z. Fischer director | AGrant or award Stock Option (right to buy)derivative | +77,000 | $0.00 | $0 | 77,000 | Jun 12, 2026 |
| Jun 10, 2026 | Michael John Tomsicek director | AGrant or award Stock Option (right to buy)derivative | +77,000 | $0.00 | $0 | 77,000 | Jun 12, 2026 |
| Jun 10, 2026 | Andrew Saik director | AGrant or award Stock Option (right to buy)derivative | +77,000 | $0.00 | $0 | 77,000 | Jun 12, 2026 |
| Jun 10, 2026 | Stuart Duty director | AGrant or award Stock Option (right to buy)derivative | +77,000 | $0.00 | $0 | 77,000 | Jun 12, 2026 |
| Jun 10, 2026 | Joseph C Papa director | AGrant or award Stock Option (right to buy)derivative | +77,000 | $0.00 | $0 | 77,000 | Jun 12, 2026 |
| Jun 10, 2026 | Lisa M. Giles director | AGrant or award Stock Option (right to buy)derivative | +77,000 | $0.00 | $0 | 77,000 | Jun 12, 2026 |
| Apr 16, 2026 | Joseph Oliveto President and CEO | SOpen-market sale Common Shares10b5-1 | -36,500 | $2.26 | $82k | 446,244 | Apr 20, 2026 |
| Feb 2, 2026 | Jeffrey Edward Nelson Chief Operating Officer | AGrant or award Employee Stock Option (right to buy)derivative | +204,000 | $0.00 | $0 | 204,000 | Feb 5, 2026 |
| Feb 2, 2026 | Lorenz Muller Chief Commercial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +204,000 | $0.00 | $0 | 204,000 | Feb 5, 2026 |
| Feb 2, 2026 | Amit Hasija CFO & EVP of Corp. Development | AGrant or award Employee Stock Option (right to buy)derivative | +204,000 | $0.00 | $0 | 204,000 | Feb 5, 2026 |
| Feb 2, 2026 | David Bharucha Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +204,000 | $0.00 | $0 | 204,000 | Feb 5, 2026 |
| Feb 2, 2026 | Joseph Oliveto President and CEO | AGrant or award Employee Stock Option (right to buy)derivative | +679,000 | $0.00 | $0 | 679,000 | Feb 5, 2026 |
| Feb 2, 2026 | Jeffrey Edward Nelson Chief Operating Officer | AGrant or award Employee Stock Option (right to buy)derivative | +204,000 | $0.00 | $0 | 204,000 | Feb 4, 2026 |
| Feb 2, 2026 | David Bharucha Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +204,000 | $0.00 | $0 | 204,000 | Feb 4, 2026 |
| Feb 2, 2026 | Joseph Oliveto President and CEO | AGrant or award Employee Stock Option (right to buy)derivative | +679,000 | $0.00 | $0 | 679,000 | Feb 4, 2026 |
| Feb 2, 2026 | Amit Hasija CFO & EVP of Corp. Development | AGrant or award Employee Stock Option (right to buy)derivative | +204,000 | $0.00 | $0 | 204,000 | Feb 4, 2026 |
| Feb 2, 2026 | Lorenz Muller Chief Commercial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +204,000 | $0.00 | $0 | 204,000 | Feb 4, 2026 |
| Feb 2, 2026 | Jeffrey Edward Nelson Chief Operating Officer | AGrant or award Restricted Stock Unitderivative | +136,000 | $0.00 | $0 | 136,000 | Feb 4, 2026 |
| Feb 2, 2026 | Lorenz Muller Chief Commercial Officer | AGrant or award Restricted Stock Unitderivative | +136,000 | $0.00 | $0 | 136,000 | Feb 4, 2026 |
| Feb 2, 2026 | David Bharucha Chief Medical Officer | AGrant or award Restricted Stock Unitderivative | +136,000 | $0.00 | $0 | 136,000 | Feb 4, 2026 |
| Feb 2, 2026 | Amit Hasija CFO & EVP of Corp. Development | AGrant or award Restricted Stock Unitderivative | +136,000 | $0.00 | $0 | 136,000 | Feb 4, 2026 |
| Feb 2, 2026 | Joseph Oliveto President and CEO | AGrant or award Restricted Stock Unitderivative | +453,000 | $0.00 | $0 | 453,000 | Feb 4, 2026 |
| Dec 12, 2025 | Joseph Oliveto President and CEO | AGrant or award Common Shares | +280,000 | - | - | 583,721 | Jan 28, 2026 |
| Dec 12, 2025 | Lorenz Muller Chief Commercial Officer | AGrant or award Common Shares | +100,000 | - | - | 250,052 | Jan 28, 2026 |
| Dec 12, 2025 | Jeffrey Edward Nelson Chief Operating Officer | AGrant or award Common Shares | +100,000 | - | - | 100,000 | Jan 28, 2026 |
| Dec 12, 2025 | David Bharucha Chief Medical Officer | AGrant or award Common Shares | +100,000 | - | - | 163,333 | Jan 28, 2026 |
| Dec 12, 2025 | Amit Hasija CFO & EVP of Corp. Development | AGrant or award Common Shares | +100,000 | - | - | 150,000 | Jan 28, 2026 |
| Dec 15, 2025 | David Bharucha Chief Medical Officer | SOpen-market sale Common Shares | -58,007 | $2.32 | $135k | 105,326 | Jan 28, 2026 |
| Dec 15, 2025 | Amit Hasija CFO & EVP of Corp. Development | SOpen-market sale Common Shares | -58,007 | $2.32 | $135k | 91,993 | Jan 28, 2026 |
| Dec 15, 2025 | Joseph Oliveto President and CEO | SOpen-market sale Common Shares | -133,054 | $2.32 | $309k | 450,667 | Jan 28, 2026 |
| Dec 15, 2025 | Lorenz Muller Chief Commercial Officer | SOpen-market sale Common Shares | -53,566 | $2.32 | $124k | 196,486 | Jan 28, 2026 |
| Dec 15, 2025 | Jeffrey Edward Nelson Chief Operating Officer | SOpen-market sale Common Shares | -58,007 | $2.32 | $135k | 41,993 | Jan 28, 2026 |
| Jan 26, 2026 | Lorenz Muller Chief Commercial Officer | MOption exercise Common Shares | +20,100 | - | - | 216,586 | Jan 28, 2026 |
| Jan 26, 2026 | Jeffrey Edward Nelson Chief Operating Officer | MOption exercise Common Shares | +20,100 | - | - | 62,093 | Jan 28, 2026 |
| Jan 26, 2026 | David Bharucha Chief Medical Officer | MOption exercise Common Shares | +20,100 | - | - | 125,426 | Jan 28, 2026 |
| Jan 26, 2026 | Amit Hasija CFO & EVP of Corp. Development | MOption exercise Common Shares | +20,100 | - | - | 112,093 | Jan 28, 2026 |
| Jan 26, 2026 | Joseph Oliveto President and CEO | MOption exercise Common Shares | +66,600 | - | - | 517,267 | Jan 28, 2026 |
| Jan 26, 2026 | Lorenz Muller Chief Commercial Officer | SOpen-market sale Common Shares | -11,180 | $1.93 | $22k | 205,406 | Jan 28, 2026 |
| Jan 26, 2026 | Jeffrey Edward Nelson Chief Operating Officer | SOpen-market sale Common Shares | -12,245 | $1.93 | $24k | 49,848 | Jan 28, 2026 |
| Jan 26, 2026 | David Bharucha Chief Medical Officer | SOpen-market sale Common Shares | -12,245 | $1.93 | $24k | 113,181 | Jan 28, 2026 |
| Jan 26, 2026 | Amit Hasija CFO & EVP of Corp. Development | SOpen-market sale Common Shares | -12,245 | $1.93 | $24k | 99,848 | Jan 28, 2026 |
| Jan 26, 2026 | Joseph Oliveto President and CEO | SOpen-market sale Common Shares | -34,523 | $1.93 | $67k | 482,744 | Jan 28, 2026 |
| Dec 12, 2025 | David Bharucha Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 28, 2026 |
| Dec 12, 2025 | Jeffrey Edward Nelson Chief Operating Officer | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 28, 2026 |
| Dec 12, 2025 | Lorenz Muller Chief Commercial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 28, 2026 |
| Dec 12, 2025 | Joseph Oliveto President and CEO | AGrant or award Employee Stock Option (right to buy)derivative | +280,000 | $0.00 | $0 | 280,000 | Jan 28, 2026 |
| Dec 12, 2025 | Amit Hasija CFO & EVP of Corp. Development | AGrant or award Employee Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 28, 2026 |
| Jan 26, 2026 | Joseph Oliveto President and CEO | MOption exercise Restricted Stock Unitsderivative | -66,600 | $0.00 | $0 | 199,800 | Jan 28, 2026 |
| Jan 26, 2026 | Lorenz Muller Chief Commercial Officer | MOption exercise Restricted Stock Unitsderivative | -20,100 | $0.00 | $0 | 60,300 | Jan 28, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- David BharuchaChief Medical Officer
- Stuart Dutydirector
- Seth H. Z. Fischerdirector
- Lisa M. Gilesdirector
- Amit HasijaCFO & EVP of Corp. Development
- Lorenz MullerChief Commercial Officer
- Jeffrey Edward NelsonChief Operating Officer
- Joseph OlivetoPresident and CEO
- Joseph C Papaceo, president, officer, director
- Andrew Saikcfo, officer, director
- Michael John Tomsicekdirector
- Robert James Willsdirector
Questions about MIST
Answered from the filings on this page, as of the latest one.
Are insiders buying MIST?
No. In the last 90 days no insider at Milestone Pharmaceuticals Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade MIST on the open market?
Joseph Oliveto (President and CEO) sold $82k of MIST on Apr 16, 2026 and filed the Form 4 on Apr 20, 2026. InsiderTell scored 14 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at Milestone Pharmaceuticals Inc.?
12 people have filed a Form 4 at Milestone Pharmaceuticals Inc., among them David Bharucha (Chief Medical Officer), Stuart Duty (director), Seth H. Z. Fischer (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.